134 related articles for article (PubMed ID: 22913714)
1. Safety and interactions of new antifungals in stem cell transplant recipients.
Girmenia C; Iori AP
Expert Opin Drug Saf; 2012 Sep; 11(5):803-18. PubMed ID: 22913714
[TBL] [Abstract][Full Text] [Related]
2. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Girmenia C; Iori AP
Expert Opin Drug Saf; 2017 Mar; 16(3):329-339. PubMed ID: 28004589
[TBL] [Abstract][Full Text] [Related]
3. Clinical hepatotoxicity associated with antifungal agents.
Kyriakidis I; Tragiannidis A; Munchen S; Groll AH
Expert Opin Drug Saf; 2017 Feb; 16(2):149-165. PubMed ID: 27927037
[TBL] [Abstract][Full Text] [Related]
4. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.
Wilson DT; Drew RH; Perfect JR
Mycopathologia; 2009 Dec; 168(6):313-27. PubMed ID: 19308672
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
6. The value of amphotericin B in the treatment of invasive fungal infections.
Klepser M
J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population.
Yang T; Wu XM; Qiu HQ; Fu DH; Hu JD; Li J; Zheng XY; Luo XF; Yuan XH; Chen RL; Chen ZZ
Clin Transplant; 2013; 27(2):255-60. PubMed ID: 23294039
[TBL] [Abstract][Full Text] [Related]
10. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
Rogers TR; Frost S
Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
12. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
13. Management of systemic fungal infections: alternatives to itraconazole.
Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
[TBL] [Abstract][Full Text] [Related]
14. Antifungal prophylaxis in the haematological patient: a practical approach.
Vázquez L; Carreras E; Serrano D; Jarque I; Mensa J; Barberán J
Rev Esp Quimioter; 2012 Dec; 25(4):299-304. PubMed ID: 23303265
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
16. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT.
Egger SS; Meier S; Leu C; Christen S; Gratwohl A; Krähenbühl S; Haschke M
Bone Marrow Transplant; 2010 Jul; 45(7):1197-203. PubMed ID: 19946342
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
19. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies.
Marr KA
Curr Opin Infect Dis; 2008 Aug; 21(4):409-14. PubMed ID: 18594294
[TBL] [Abstract][Full Text] [Related]
20. Antifungal drugs.
Treat Guidel Med Lett; 2008 Jan; 6(65):1-8. PubMed ID: 18157085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
